{"schema_version":"secwatch.filing_event.v1","accession":"0001100682-24-000025","form_type":"8-K","ticker":"CRL","cik":"0001100682","company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.173077+00:00","generated_at":"2026-05-31T11:35:52.034103+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Charles River Q2 revenue falls 3.2% to $1.03B; slashes FY24 guidance on weak demand","bullets":["GAAP EPS $1.74 (-7.9% YoY); Non-GAAP EPS $2.80 (+4.1%), Non-GAAP net income $144.9M (+4.8%).","DSA organic revenue -5.0%, RMS organic -3.9%; Manufacturing organic +3.7%.","Board authorized new $1.0B share repurchase plan, replacing prior $1.3B authorization.","FY24 guided GAAP EPS $5.65-$5.95 (prior $7.60-$8.10); Non-GAAP EPS $9.90-$10.20 (prior $10.90-$11.40).","Restructuring expected to yield >$150M annual savings; ~$100M realized in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001100682-24-000025","json":"https://secwatch.observer/filing/0001100682-24-000025.json","markdown":"https://secwatch.observer/filing/0001100682-24-000025.md","text":"https://secwatch.observer/filing/0001100682-24-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1100682/000110068224000025/0001100682-24-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1100682/000110068224000025/crl-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:35:52.034103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}